PL2217219T3 - Podjęzykowa musująca tabletka progesteronu w połączeniu z cyklodekstryną - Google Patents

Podjęzykowa musująca tabletka progesteronu w połączeniu z cyklodekstryną

Info

Publication number
PL2217219T3
PL2217219T3 PL08805213T PL08805213T PL2217219T3 PL 2217219 T3 PL2217219 T3 PL 2217219T3 PL 08805213 T PL08805213 T PL 08805213T PL 08805213 T PL08805213 T PL 08805213T PL 2217219 T3 PL2217219 T3 PL 2217219T3
Authority
PL
Poland
Prior art keywords
sublingual
cyclodextrin
effervescent tablet
progesterone
progesterone associated
Prior art date
Application number
PL08805213T
Other languages
English (en)
Inventor
Lorenzo Bellorini
Luca Nocelli
Giorgio Zoppetti
Original Assignee
Altergon Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altergon Sa filed Critical Altergon Sa
Publication of PL2217219T3 publication Critical patent/PL2217219T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
PL08805213T 2007-10-10 2008-10-10 Podjęzykowa musująca tabletka progesteronu w połączeniu z cyklodekstryną PL2217219T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001971A ITMI20071971A1 (it) 2007-10-10 2007-10-10 Composizione farmaceutica per la somministrazione sublinguale di progesterone, e metodo per la sua preparazione
EP08805213A EP2217219B1 (en) 2007-10-10 2008-10-10 A sublingual effervescent tablet of progesterone associated with cyclodextrin
PCT/EP2008/063595 WO2009047321A2 (en) 2007-10-10 2008-10-10 A sublingual effervescent tablet of progesterone associated with cyclodextrin

Publications (1)

Publication Number Publication Date
PL2217219T3 true PL2217219T3 (pl) 2012-05-31

Family

ID=40313810

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08805213T PL2217219T3 (pl) 2007-10-10 2008-10-10 Podjęzykowa musująca tabletka progesteronu w połączeniu z cyklodekstryną

Country Status (13)

Country Link
US (2) US9066858B2 (pl)
EP (1) EP2217219B1 (pl)
JP (1) JP2011500534A (pl)
KR (1) KR20100077159A (pl)
CN (1) CN101854923B (pl)
AT (1) ATE536865T1 (pl)
CA (1) CA2701857C (pl)
DK (1) DK2217219T3 (pl)
ES (1) ES2378917T3 (pl)
IT (1) ITMI20071971A1 (pl)
PL (1) PL2217219T3 (pl)
PT (1) PT2217219E (pl)
WO (1) WO2009047321A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011021805A2 (ko) 2009-08-18 2011-02-24 주식회사 엘지화학 신규한 화합물, 이를 포함하는 촉매 조성물 및 이를 이용한 고리형 올레핀계 중합체의 제조방법
US20110312928A1 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
CA2853117C (en) * 2011-10-25 2018-08-07 Expermed S.A. Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
ITMI20122027A1 (it) 2012-11-28 2014-05-29 Altergon Sa Soluzioni acquose orali di ormoni steroidei e hp¿cd con biodisponibilità ottimizzata
CN103877048A (zh) * 2014-03-26 2014-06-25 邵娜 一种黄体酮口腔崩解片及其制备方法
ITUB20161027A1 (it) 2016-02-24 2017-08-24 Altergon Sa Preparazioni farmaceutiche oromucosali ad elevata biodisponibilita’ a base di ciclodestrina e sucralosio
WO2018117855A1 (en) * 2016-12-20 2018-06-28 X-Ing As Effervescent lozenge
NO20171457A1 (no) * 2016-12-20 2018-06-21 X Ing As Effervesent sugetablett
CA3074563A1 (en) * 2017-09-06 2019-03-14 pHase Pharmaceuticals LLC Sublingual epinephrine tablets
CN109381424A (zh) * 2018-11-21 2019-02-26 南京泽恒医药技术开发有限公司 稳定的黄体酮水溶注射剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1419074A (en) * 1972-06-09 1975-12-24 Ici Ltd Process for manufacturing substituted thiophene compounds
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
CZ131695A3 (en) * 1992-11-23 1996-05-15 Pfizer Process for preparing 4-chloro-2-thiophenecarboxylic acid, intermediates for its preparation and process for preparing 5-fluoro-6-chloro-3-(4-chloro-2-thenoyl)-2-oxindole-1-carboxamide
US6323227B1 (en) * 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6037340A (en) * 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
DE10061876A1 (de) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
JP2005511613A (ja) * 2001-11-08 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 疾患治療用アザビシクロ置換ヘテロアリール化合物
AU2003265255A1 (en) * 2002-07-01 2004-01-19 Finzel, Barry, C. Inhibitors of hcv ns5b polymerase
US20050142197A1 (en) * 2003-12-31 2005-06-30 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering

Also Published As

Publication number Publication date
US9066858B2 (en) 2015-06-30
ITMI20071971A1 (it) 2009-04-11
CA2701857C (en) 2015-03-24
WO2009047321A3 (en) 2009-07-09
ATE536865T1 (de) 2011-12-15
CN101854923B (zh) 2012-04-18
ES2378917T3 (es) 2012-04-19
PT2217219E (pt) 2012-03-29
CN101854923A (zh) 2010-10-06
EP2217219B1 (en) 2011-12-14
CA2701857A1 (en) 2009-04-16
JP2011500534A (ja) 2011-01-06
US20100240631A1 (en) 2010-09-23
WO2009047321A2 (en) 2009-04-16
US20150265631A1 (en) 2015-09-24
EP2217219A2 (en) 2010-08-18
KR20100077159A (ko) 2010-07-07
DK2217219T3 (da) 2012-03-12

Similar Documents

Publication Publication Date Title
PL2217219T3 (pl) Podjęzykowa musująca tabletka progesteronu w połączeniu z cyklodekstryną
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
WO2010146179A3 (en) Solid pharmaceutical composition comprising rivaroxaban
WO2007121318A3 (en) Formulations for delivering insulin
MY158261A (en) Pharmaceutical com[osition comprising a strontium salt, vitamin d and a cyclodextrin
WO2006119498A3 (en) Pharmaceutical compositions with synchronized solubilizer release
IL216522A (en) Durable dosage form, packing containing it and method of preparation
MX2013007057A (es) Metodos para producir composiciones farmaceuticas estabilizadas de dosis solida que contienen morfinanos.
HK1148202A1 (en) Pharmaceutical solutions, process of preparation and therapeutic uses
WO2010031720A3 (en) Novel antibody formulation
WO2010117738A3 (en) Solid state forms of sitagliptin salts
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
WO2007144169A3 (en) Entacapone-derivatives
MX356801B (es) Incremento en la biodisponibilidad de fármacos en la terapia con naltrexona.
IN2012DN02793A (pl)
WO2010049449A3 (en) Novel salts of sunitinib
AP2010005343A0 (en) New dihydroindolone compounds, a process for theirpreparation and pharmaceutical compositions conta ining them.
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
WO2009022327A3 (en) Novel process for preparing highly pure levocetirizine and salts thereof
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
WO2010148314A3 (en) Preparation of esomeprazole and its pharmaceutically acceptable salts
WO2011087765A3 (en) Methods of producing stabilized solid pharmaceutical compositions containing morphinans
WO2010032006A8 (en) Treatment of adrenal insufficiency
PT2451446E (pt) Composição para a produção de comprimidos e processo para a sua produção